drugset / Trial / NCT05407961
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 16 weeks excluding screening period for each part, respectively.
Timeline
- Start
- 2022-06-07
- Primary completion
- 2024-01-12
- Completion
- 2024-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Macupatide | Protein / enzyme biologic | — | Subcutaneous |
| Background | Dulaglutide | Peptide | — | Subcutaneous |